Tyrosine kinase inhibitorFDA-approvedSecond-line
Osimertinib
How it works
Blocks the epidermal growth factor receptor (EGFR) on cancer cells, preventing them from growing and dividing.
Cancer types
Lung Cancer— EGFR-mutated
Efficacy
Studies show that osimertinib can improve response rates in patients with EGFR-mutated non-small cell lung cancer, with an objective response rate of approximately 80%.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Researchers Find New Way to Rechallenge Cancer Drug After Severe Reaction | Lung Cancer | observational | — | Source → |
| Testing Treatments for EGFR-Mutated Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Combination Therapy for Advanced Lung Cancer: A Clinical Trial | Lung Cancer | phase-3 | — | Source → |
| Combination Therapy for Advanced Lung Cancer After Osimertinib Failure | Lung Cancer | phase-3 | — | Source → |
| Osimertinib Linked to Rare but Fatal Lung Inflammation in Lung Cancer Patients | Lung Cancer | observational | — | Source → |
| Combination Therapy Trial for Advanced Lung Cancer Patients | Lung Cancer | phase-2 | — | Source → |
| Testing Combination Therapy for Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Evaluating Osimertinib for Lung Cancer with EGFR Mutation | Lung Cancer | phase-2 | — | Source → |
| Osimertinib Study for Early Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Testing Durvalumab and Radiation Therapy in Early Stage Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Osimertinib Resistance in Lung Cancer Linked to Altered Lipid Metabolism | Lung Cancer | lab-study | — | Source → |
| Study of BL-B01D1 and Osimertinib for Lung Cancer Treatment | Lung Cancer | phase-3 | — | Source → |
| Muscle Loss in Lung Cancer Patients on Osimertinib Treatment | Lung Cancer | observational | SMI loss was an independent predictor of shorter OS (median OS 25.5 vs. 29.8 months, aHR: 2.04 [95% CI, 1.02-4.09]; P = 0.045) | Source → |
| Osimertinib Maintains Quality of Life in Lung Cancer Patients | Lung Cancer | phase-3 | — | Source → |
| Testing Ivonescimab with Other Treatments for Non-Small Cell Lung Cancer | Lung Cancer | phase-1 | — | Source → |
| Osimertinib Resistance in Lung Cancer Linked to Metabolic Regulation | Lung Cancer | lab-study | — | Source → |
| Testing a New Combination Therapy for Advanced Lung Cancer | Lung Cancer | phase-1 | — | Source → |
| Osimertinib, Surgery, and Radiation Therapy in Treating Non-small Cell Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Osimertinib and Bevacizumab for EGFR Positive Non-Small Cell Lung Cancer with Brain Metastases | Lung Cancer | phase-2 | — | Source → |
| Osimertinib Efficacy in Lung Cancer Patients with EGFR Mutations | Lung Cancer | observational | The overall survival was significantly longer in the postoperative group than in the Stage IV group (median: 39.2 months and 28.5 months, respectively). | Source → |
| Evaluating Osimertinib with Chemotherapy for Non-small Cell Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Comparing Cancer Treatment Models for Lung Cancer Patients | Lung Cancer | phase-3 | — | Source → |
| Durvalumab and Chemotherapy Tested in Lung Cancer Patients | Lung Cancer | phase-2 | Confirmed ORR was 16% (80% confidence interval: 7-30); response was maintained for more than 6 months in the four patients with confirmed response. | Source → |
| Improving Osimertinib Resistance in Lung Cancer Cells | Lung Cancer | lab-study | — | Source → |
| Sequential Afatinib and Osimertinib Therapy Shows Promise in Lung Cancer | Lung Cancer | observational | Sequential afatinib-osimertinib therapy achieved a median OS of 55 months compared to 32.3 months with alternative strategies. | Source → |
| Combining Osimertinib and Brain Radiation for Advanced Lung Cancer | Lung Cancer | preclinical | — | Source → |
| Combining Osimertinib with AKR1C3 Inhibitor May Help Overcome Lung Cancer Resistance | Lung Cancer | lab-study | — | Source → |
| Combining two cancer drugs may improve lung cancer treatment | Lung Cancer | phase-3 | The combination nearly doubled progression-free survival (PFS) compared with chemotherapy (9.8 vs. 5.4 months; hazard ratio 0.34) | Source → |
| Osimertinib Linked to Increased Heart Risks | Lung Cancer | meta-analysis | — | Source → |
| Osimertinib with or without Chemotherapy in Lung Cancer Patients | Lung Cancer | phase-3 | Combining osimertinib with chemotherapy improved progression-free survival versus osimertinib alone (HR, 0.62; P < 0.001). | Source → |
| Understanding Resistance to Osimertinib in Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Osimertinib Resistance in Lung Cancer Patients | Lung Cancer | observational | — | Source → |
| Lung Cancer Treatment Study | Lung Cancer | phase-1 | — | Source → |
| Cancer Cells May Use Special Structures to Resist Treatment | Lung Cancer | lab-study | — | Source → |
| New Combo Helps Lung Cancer Patients | Lung Cancer | phase-2 | Confirmed ORR was 43% (80% CI 32-55) and 36% (80% CI 25-49) | Source → |
| Osimertinib Helps Unresectable Lung Cancer | Lung Cancer | phase-3 | The PFS hazard ratio was 0.16. | Source → |
| Cost-effectiveness of Osimertinib for Lung Cancer Patients | Lung Cancer | observational | — | Source → |
| Researchers Explore Ways to Overcome Resistance to Osimertinib in Lung Cancer | Lung Cancer | lab-study | — | Source → |
| Osimertinib Treatment in Lung Cancer | Lung Cancer | observational | Significant improvement in disease-free survival among patients with stage IB-IIIA epidermal growth factor receptor mutation positive (EGFRm+) non-small cell lung carcinoma (NSCLC) was associated with adjuvant osimertinib, showing a 73.2% of patients were mainly females. | Source → |
| Osimertinib Resistance in Lung Cancer: A New Signaling Pathway Identified | Lung Cancer | lab-study | — | Source → |
| Rare Lung Cancer Mutation Responds to Afatinib and Osimertinib | Lung Cancer | observational | — | Source → |
| Osimertinib May Help Some Lung Cancer Patients with Specific Mutation | Lung Cancer | observational | The patient achieved a progression-free survival of 10 months. | Source → |
| Osimertinib and Chemotherapy Combination Shows Promise in Lung Cancer | Lung Cancer | phase-3 | The experimental group demonstrated longer median progression-free survival (15.7 vs 10.6 months) and overall survival (24.6 vs 17.5 months) compared to the control group. | Source → |
| Osimertinib Effective for Lung Cancer Patients with EGFR Mutation | Lung Cancer | meta-analysis | Osimertinib demonstrated significantly superior objective response rate (ORR) compared to control treatments (relative risk [RR] = 1.59, 95% confidence interval [CI] = 1.16 to 2.17, p < .001), exceeding the minimal clinically important difference threshold. | Source → |
| Osimertinib May Cause Heart Problems in Lung Cancer Patients | Lung Cancer | observational | — | Source → |
| Osimertinib Response Linked to Gene Mutation Frequency | Lung Cancer | observational | Patients with a variant allele frequency (VAF) ≥30% showed a mean overall survival of 31.4 months and a mean progression-free survival of 25.0 months. | Source → |
| New Study Examines Osimertinib Effectiveness in Lung Cancer Patients | Lung Cancer | phase-2 | The objective response rate was 61.8%, and grade 3 or higher adverse events occurred in 22.1% of the patients. | Source → |
| Genetic Changes in Lung Cancer Patients Predict Treatment Outcomes | Lung Cancer | observational | Patients with mutations in exon 5 had a hazard ratio of 7.67 for reduced treatment period and 9.29 for overall survival compared to wild-type patients. | Source → |
| Gene Linked to Osimertinib Resistance | Lung Cancer | lab-study | — | Source → |
| Eugenol May Help Overcome Lung Cancer Resistance to Osimertinib | Lung Cancer | lab-study | — | Source → |
| PD-L1 Expression May Affect Osimertinib Outcomes in Lung Cancer | Lung Cancer | meta-analysis | Higher PD-L1 expression (≥50%) was associated with a 3.03-fold increased risk of progression or death. | Source → |
| Researchers Find New Way to Overcome Osimertinib Resistance in Lung Cancer | Lung Cancer | lab-study | — | Source → |
| Osimertinib Monotherapy for Advanced Lung Cancer with Atypical EGFR Mutations | Lung Cancer | observational | Median progression-free survival was 8.8 months, and median overall survival was 28.5 months overall, 42.5 months in patients with compound EGFR mutations, and 20.0 months in those with atypical mutations alone. | Source → |
| Gene Amplification Linked to Osimertinib Efficacy in Lung Cancer | Lung Cancer | observational | Overall survival was significantly shorter for actinin-4 immunohistochemistry-positive patients than for actinin-4 immunohistochemistry-negative patients (hazard ratio, 2.76; 95% confidence interval, 1.02-7.45). | Source → |
| Understanding Drug-Tolerant Cancer Cells in Lung Cancer | Lung Cancer | lab-study | Notably, this strategy showed superior efficacy compared with osimertinib combinations with chemotherapy or AXL inhibitor in both settings. | Source → |
| PD-L1's Role in Lung Cancer Resistance to Osimertinib | Lung Cancer | lab-study | — | Source → |
| New Cancer Compound Shows Promise in Lung Cancer Research | Lung Cancer | lab-study | Compound 14l achieved the lowest IC₅₀ values and strong EGFR kinase inhibition (IC₅₀ = 50.58 ± 3.87 nM). | Source → |
| New Compound May Help Overcome Lung Cancer Resistance to Osimertinib | Lung Cancer | lab-study | — | Source → |
| Osimertinib Effective in Advanced Lung Cancer Patients | Lung Cancer | observational | The median progression-free survival was 15.8 months, and the median overall survival was 29.3 months. | Source → |
| Understanding Resistance to Osimertinib in Lung Cancer | Lung Cancer | lab-study | — | Source → |
| Osimertinib as First-Line Treatment for Lung Cancer | Lung Cancer | observational | The median first-line progression-free survival was 19.0 months in the osimertinib group. | Source → |
| PET Scans May Help Predict Lung Cancer Treatment Outcomes | Lung Cancer | observational | — | Source → |
| T cell immunity may slow down lung cancer resistance to treatment | Lung Cancer | observational | Patients with higher CXCR3CCR4CCR6CD4 T cell levels exhibited significantly enhanced PFS (p = 0.002) and OS (p = 0.0006). | Source → |
| New Study Compares Cancer Treatments for Lung Cancer Patients | Lung Cancer | meta-analysis | Osimertinib resulted in significantly longer overall survival compared to erlotinib-based regimens (HR for OS vs. erlotinib: 1.59, 95% CI 1.09-2.31). | Source → |
| Radiation Therapy Extends Time on Osimertinib for Some Lung Cancer Patients | Lung Cancer | observational | After XRT, time on osimertinib was extended for a median of 9.7 months, with a median progression-free survival (PFS) and overall survival of 6.9 and 24.4 months, respectively. | Source → |
| Osimertinib Effective in Treating Lung Cancer with Brain Metastases | Lung Cancer | observational | The CNS-ORR was 91.9% and the CNS-DCR was 100%. | Source → |
| Rare Side Effect of Osimertinib in Lung Cancer Treatment | Lung Cancer | observational | — | Source → |
| Understanding Resistance to Lung Cancer Drugs | Lung Cancer | lab-study | — | Source → |
| New Approach to Treating Lung Cancer Resistant to Osimertinib | Lung Cancer | lab-study | — | Source → |
| MDM2 protein linked to resistance to cancer treatment Osimertinib | Lung Cancer | lab-study | — | Source → |
| Comparing Treatments for Lung Cancer with EGFR Mutations | Lung Cancer | phase-3 | The median progression-free survival (PFS) did not differ significantly between 2 G EGFR-TKIs and osimertinib (del 19: 17.6 months; L858R: 20.0 months vs. 28.3 months, p = 0.081). | Source → |
| New Study Examines Treatment Options for Lung Cancer Patients | Lung Cancer | observational | The objective response rate was much higher in the immunotherapy + chemotherapy group compared with chemotherapy or osimertinib + bevacizumab group (55.56% vs. 14.81% vs. 0%). | Source → |
| Osimertinib Helps Patient with Lung Cancer | Lung Cancer | observational | — | Source → |
| Researchers Identify Resistance Mutations in Lung Cancer Treatment | Lung Cancer | lab-study | — | Source → |
| Researchers Explore New Treatment for Lung Cancer Resistance | Lung Cancer | lab-study | — | Source → |
| Osimertinib Efficacy and Safety in Advanced Lung Cancer Patients | Lung Cancer | observational | The median progression-free survival was 20.0 months and the median overall survival was 41.0 months. | Source → |
| Ganoderma Protein May Help Fight Lung Cancer Cells Resistant to Osimertinib | Lung Cancer | lab-study | — | Source → |
| New Combination Therapy Shows Promise for Lung Cancer Treatment | Lung Cancer | lab-study | — | Source → |
| Osimertinib Shows Promise in Treating Rare Lung Cancer Mutations | Lung Cancer | phase-2 | — | Source → |
| Osimertinib as Neoadjuvant Therapy for Lung Cancer | Lung Cancer | phase-2 | The major pathological response rate was 14.8% (95% CI, 4.2 to 33.7). | Source → |
| Targeted therapy shrinks lung lesions and improves bone metastases in lung cancer patient | Lung Cancer | observational | — | Source → |
| Cancer Cells Adapt to Treatment with EGFR Inhibitors | Lung Cancer | lab-study | Combining osimertinib with elesclomol significantly increases the efficacy of osimertinib, with no additional toxicity. | Source → |
| Rare Lung Cancer Mutation Responds to Osimertinib | Lung Cancer | observational | — | Source → |
| Reduced Dosing of Osimertinib May Be a Treatment Option for Lung Cancer | Lung Cancer | observational | The objective response rate was 31.8%, and the disease control rate was 72.7%. | Source → |
| Osimertinib Effective in Rare Lung Cancer Cases | Lung Cancer | phase-2 | The overall response rate was 55.0%. | Source → |
| Predicting Osimertinib Effectiveness in Brain Cancer | Lung Cancer | lab-study | The radiomic model showed an area under the receiver operating characteristic curve (AUC) of 0.786 for the validation cohort. | Source → |
| Rare Blood Disorder Linked to Lung Cancer Treatment | Lung Cancer | observational | — | Source → |
| Combining Radiation and Osimertinib Treatments for Lung Cancer | Lung Cancer | meta-analysis | Osimertinib and similar third-generation EGFR-TKIs performed better in the brain, helping patients with central nervous system (CNS) responses of 60% to 91%. | Source → |
| Osimertinib May Be a Viable Second-Line Treatment for Lung Cancer | Lung Cancer | observational | The best tumor response rate was 42.7%, with a median time on treatment of 5.6 months. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.